GENETIC SIGNATURES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 AUD | 0.00% |
|
+0.72% | +60.92% |
| Feb. 21 | Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Jan. 24 | Genetic Signatures Completes Rights Issue | MT |
| Sales 2024 * | 10.1M 6.49M | Sales 2025 * | 26.2M 16.82M | Capitalization | 131M 83.82M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M -10.92M | Net income 2025 * | -6M -3.85M | EV / Sales 2024 * | 10.9 x |
| Net cash position 2024 * | 20M 12.84M | Net cash position 2025 * | 7M 4.49M | EV / Sales 2025 * | 4.72 x |
| P/E ratio 2024 * |
-7.45
x | P/E ratio 2025 * |
-19.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.08% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +0.72% | ||
| Current month | +2.94% | ||
| 1 month | +10.24% | ||
| 3 months | +41.41% | ||
| 6 months | +42.86% | ||
| Current year | +60.92% |
1 week
0.68
0.70
1 month
0.640.70
Current year
0.410.75
1 year
0.380.85
3 years
0.381.86
5 years
0.382.94
10 years
0.242.94
| Managers | Title | Age | Since |
|---|---|---|---|
John Melki
CEO | Chief Executive Officer | - | 02-12-31 |
Karl Pechmann
DFI | Director of Finance/CFO | - | 23-06-25 |
Douglas Millar
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Radford
BRD | Director/Board Member | - | 15-09-14 |
Caroline Waldron
BRD | Director/Board Member | - | 22-05-12 |
Michael Aicher
BRD | Director/Board Member | 64 | 14-01-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 0.7 | 0.00% | 18 |
| 24-04-16 | 0.7 | +0.72% | 49,061 |
| 24-04-15 | 0.695 | +0.72% | 8,874 |
| 24-04-12 | 0.69 | -0.72% | 56,672 |
| 24-04-11 | 0.695 | 0.00% | 21,755 |
Delayed Quote Australian S.E., April 17, 2024 at 02:10 am EDT
More quotes
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Companyâs principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit and others.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7
AUD
Average target price
0.75
AUD
Spread / Average Target
+7.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.92% | 83.8M | |
| +2.02% | 209B | |
| +2.17% | 177B | |
| +10.45% | 133B | |
| +16.62% | 99.89B | |
| -2.70% | 61.83B | |
| +13.38% | 52.51B | |
| -6.33% | 45.54B | |
| -4.74% | 39.43B | |
| +9.89% | 38.87B |
- Stock Market
- Equities
- GSS Stock
